Income Statement Olympus Corporation
Equities
7733
JP3201200007
Advanced Medical Equipment & Technology
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,224.00 JPY | -1.18% |
|
-1.81% | -6.18% |
Dec. 05 | Shareholder Derivative Lawsuit Against Olympus Former Directors, Auditors Dismissed | MT |
Nov. 27 | Former Olympus CEO indicted on allegation of illegal drug purchase, TBS says | RE |
Fiscal Period: March | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 797B | 731B | 869B | 882B | 936B | |||||
Total Revenues | 797B | 731B | 869B | 882B | 936B | |||||
Cost of Goods Sold, Total | 298B | 271B | 297B | 285B | 311B | |||||
Gross Profit | 500B | 460B | 572B | 597B | 625B | |||||
Selling General & Admin Expenses, Total | 367B | 325B | 371B | 386B | 438B | |||||
Provision for Bad Debts | - | - | - | - | - | |||||
R&D Expenses | - | - | - | - | - | |||||
Depreciation & Amortization - (IS) | 38.33B | 31.54B | 34.19B | 34.15B | 35.29B | |||||
Amortization of Goodwill and Intangible Assets - (IS) | - | - | - | - | - | |||||
Other Operating Expenses | 4.57B | 1.63B | -2.25B | 4.22B | 37.67B | |||||
Other Operating Expenses, Total | 410B | 359B | 403B | 425B | 511B | |||||
Operating Income | 89.98B | 101B | 169B | 172B | 114B | |||||
Interest Expense, Total | -3.81B | -3.99B | -4.86B | -5.86B | -5.41B | |||||
Interest And Investment Income | 1.91B | 1.17B | 1.18B | 3.74B | 2.38B | |||||
Net Interest Expenses | -1.9B | -2.82B | -3.68B | -2.12B | -3.03B | |||||
Income (Loss) On Equity Invest. | 485M | 595M | 1.49B | 491M | -358M | |||||
Currency Exchange Gains (Loss) | -3.2B | -2.1B | -158M | -2.14B | -4.49B | |||||
Other Non Operating Income (Expenses) | -567M | 2.13B | -186M | -49M | -224M | |||||
EBT, Excl. Unusual Items | 84.79B | 98.68B | 166B | 168B | 106B | |||||
Restructuring Charges | -3.95B | -23.64B | -18.73B | -2.36B | -5.85B | |||||
Gain (Loss) On Sale Of Investments | - | 1.77B | 2.83B | - | - | |||||
Gain (Loss) On Sale Of Assets | - | - | 1.39B | 16.4B | 1.13B | |||||
Asset Writedown | -3.04B | - | -1.63B | - | -65.54B | |||||
Legal Settlements | - | - | - | - | - | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | 77.8B | 76.81B | 150B | 182B | 35.85B | |||||
Income Tax Expense | 26.14B | 11.14B | 33.9B | 44.3B | 8.88B | |||||
Earnings From Continuing Operations | 51.66B | 65.67B | 116B | 138B | 26.97B | |||||
Earnings Of Discontinued Operations | - | -52.68B | - | 5.62B | 216B | |||||
Net Income to Company | 51.66B | 12.99B | 116B | 144B | 243B | |||||
Minority Interest | 15M | -71M | -228M | -181M | -363M | |||||
Net Income - (IS) | 51.67B | 12.92B | 116B | 143B | 243B | |||||
Net Income to Common Incl Extra Items | 51.67B | 12.92B | 116B | 143B | 243B | |||||
Net Income to Common Excl. Extra Items | 51.67B | 65.6B | 116B | 138B | 26.61B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 39.37 | 10.05 | 90.22 | 113.22 | 199.91 | |||||
Basic EPS - Continuing Operations | 39.37 | 51.03 | 90.22 | 108.78 | 21.93 | |||||
Basic Weighted Average Shares Outstanding | 1.31B | 1.29B | 1.28B | 1.27B | 1.21B | |||||
Net EPS - Diluted | 39.36 | 10.04 | 90.17 | 113.08 | 199.44 | |||||
Diluted EPS - Continuing Operations | 39.36 | 51 | 90.17 | 108.65 | 21.88 | |||||
Diluted Weighted Average Shares Outstanding | 1.31B | 1.29B | 1.28B | 1.27B | 1.22B | |||||
Normalized Basic EPS | 40.4 | 47.92 | 80.7 | 82.87 | 54.36 | |||||
Normalized Diluted EPS | 40.38 | 47.89 | 80.66 | 82.77 | 54.23 | |||||
Dividend Per Share | 10 | 12 | 14 | 16 | 18 | |||||
Payout Ratio | 19.82 | 99.52 | 13.33 | 12.43 | 8.27 | |||||
American Depositary Receipts Ratio (ADR) | 1 | 1 | 1 | 1 | 1 | |||||
Supplemental Items | ||||||||||
EBITDA | 158B | 161B | 233B | 239B | 180B | |||||
EBITA | 89.98B | 101B | 169B | 172B | 114B | |||||
EBIT | 89.98B | 101B | 169B | 172B | 114B | |||||
Effective Tax Rate - (Ratio) | 33.6 | 14.5 | 22.62 | 24.3 | 24.77 | |||||
Normalized Net Income | 53.01B | 61.6B | 104B | 105B | 65.96B | |||||
Non-Cash Pension Expense | 15.9B | 19.06B | 20.5B | 19.27B | 20.68B | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 21.5B | 11.75B | 15.17B | 15.45B | 16.19B | |||||
Selling and Marketing Expenses | 21.5B | 11.75B | 15.17B | 15.45B | 16.19B | |||||
Research And Development Expense From Footnotes | 91.6B | 81.8B | 85.3B | 76.9B | 86.4B |